Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic diseases

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

- PMLiVE

Daily Brief: GDPR and NHS Opt Out Day, BioMarin’s new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

NHS seeks ‘solution creators’ from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

- PMLiVE

Judge forces NHS England rethink on Kuvan

The health service claims the drug is not clinically effective

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

Living with Crohn’s disease: a patient perspective

Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for...

Blue Latitude Health

Understanding the Chronic Disease Patient Journey in Emerging Markets

The benefits of understanding the patient journey are well documented in mature markets. But in emerging markets the patient journey is less understood. We recently presented a webinar hosted by...

Research Partnership

- PMLiVE

Teva expands eHealth alliance with IBM

Taps Watson Health Cloud for drug development and disease management work

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links